Know Cancer

or
forgot password


Phase 2/Phase 3
18 Years
N/A
Not Enrolling
Female
Breast Cancer, Musculoskeletal Disease

Thank you

Trial Information


Inclusion Criteria:



- Postmenopausal status

- Currently being treated with an AI in the adjuvant setting (minimum for 8 weeks)

- AIMSS as determined by new or worsened musculoskeletal complaints following AI
therapy

- Vitamin D deficiency (<30ng/ml)

- Caucasian

Exclusion Criteria:

-

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

Change from baseline in musculoskeletal pain and 250HD levels

Outcome Time Frame:

3 monthly during one year

Safety Issue:

No

Authority:

Belgium: Federal Agency for Medicines and Health Products, FAMHP

Study ID:

s55283

NCT ID:

NCT01809171

Start Date:

May 2013

Completion Date:

Related Keywords:

  • Breast Cancer
  • Musculoskeletal Disease
  • Breast Neoplasms
  • Musculoskeletal Diseases

Name

Location